GlassScriptPhysician profile
Jill D Langley
NPI 1194161414
$2,155.79
in general payments reported to CMS, 2019-2025
26 companies · $939 in 2025
The $939 reported for 2025 was more than what 96% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $165 · 2022: $171 · 2023: $131 · 2024: $750 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $277.93 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $190.29 | 2024-2025 | |
| Lilly USA, LLC | $183.73 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $167.26 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.37 | 2021-2025 | Xifaxan |
| Corium, LLC | $137.84 | 2022-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $135.33 | 2025 | |
| Abbott Laboratories | $103.58 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $91.95 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $88.26 | 2024-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $74.13 | 2024-2025 | Breztri, Nexium |
| Exact Sciences Corporation | $72.56 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $71.31 | 2024-2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $61.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $54.02 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.68 | 2024-2025 | Repatha, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $40.89 | 2024-2025 | Gvoke Hypopen, Keveyis |
| Glaxosmithkline, LLC. | $40.88 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Kowa Pharmaceuticals America, INC. | $28.08 | 2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $25.60 | 2025 | Fanapt |
| Phathom Pharmaceuticals, INC. | $25.39 | 2024 | Voquezna |
| Insulet Corporation | $20.42 | 2025 | Omnipod |
| Organogenesis INC. | $15.81 | 2025 | Affinity |
| Collegium Pharmaceutical, INC. | $15.22 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.53 | 2024 | Caplyta |
| Paratek Pharmaceuticals, INC. | $13.02 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Langley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.